|
|
||||||||
Technical Briefs |
1 Laboratory for Prenatal Medicine, University Womens Hospital, and Department of Research, University Hospital Basel, Basel, Switzerland;2 University Womens Hospital, University Hospital Basel, Basel, Switzerland;
aaddress correspondence to this author at: Laboratory for Prenatal Medicine, University Womens Hospital, University Hospital Basel, Spitalstrasse 21, CH-4031 Basel, Switzerland; fax 41-61-265-9399, e-mail shahn@uhbs.ch
| The first 20% of the full text of this article appears below. |
Several studies using quantitative real-time PCR to measure fetal DNA and mRNA in maternal plasma have suggested that their concentrations could indicate the presence of certain pregnancy-related disorders or predispositions to them (1). Significant increases in the median concentration of cell-free fetal DNA have been reported in pregnancies bearing aneuploid fetuses (2)(3), in those affected by or at risk for preeclampsia (4)(5)(6)(7)(8), or those with preterm labor (9). Fetally derived corticotropin-releasing hormone (CRH) mRNA is reportedly increased in pregnancies with manifest preeclampsia (10), and human chorionic gonadotropin ß-subunit mRNA has been reported to be increased in pregnancies with aneuploid fetuses (11).
In this study, we measured CRH mRNA by a real-time quantitative reverse transcription-PCR assay (10)(12) in women with preterm labor. Preterm delivery remains a leading cause of perinatal mortality, has an unchanged incidence of almost 7% over the past decade (13)(14), and has no known etiology. No test
The following articles in journals at HighWire Press have cited this article:
![]() |
X. Y. Zhong, S. Gebhardt, R. Hillermann, K. C. Tofa, W. Holzgreve, and S. Hahn Parallel Assessment of Circulatory Fetal DNA and Corticotropin-Releasing Hormone mRNA in Early- and Late-Onset Preeclampsia Clin. Chem., September 1, 2005; 51(9): 1730 - 1733. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |